ERS | Jotup

ERS electronic Announces Agreement with Geringer Halbleitertechnik GmbH & Co. KG to Strengthen R&D and Production Capabilities

Retrieved on:

Tuesday, April 9, 2024

Small Business Saturday, Research, Head, Education minister, Retirement, ERS

MUNICH, April 9, 2024 /PRNewswire/ -- ERS electronic , the industry leader of thermal management solutions for semiconductor manufacturing has finalized an agreement with Geringer Halbleitertechnik GmbH & Co. KG , a move poised to bolster its research and development (R&D) and production capabilities.

Key Points:

MUNICH, April 9, 2024 /PRNewswire/ -- ERS electronic , the industry leader of thermal management solutions for semiconductor manufacturing has finalized an agreement with Geringer Halbleitertechnik GmbH & Co. KG , a move poised to bolster its research and development (R&D) and production capabilities.
Geringer was founded in 1991 and has established itself as a reputable developer and manufacturer of tailor-made manufacturing machines for the semiconductor industry.
"We are thrilled to welcome the team from Geringer to ERS and expand our APEqS Business Unit," says Laurent Giai-Miniet, CEO of ERS electronic.
As I transition into retirement, I wish ERS all the best and am excited to see the great things they will accomplish."

ERS electronic Announces Agreement with Geringer Halbleitertechnik GmbH & Co. KG to Strengthen R&D and Production Capabilities

Retrieved on:

Tuesday, April 9, 2024

Small Business Saturday, Research, Head, Education minister, Retirement, ERS

MUNICH, April 9, 2024 /PRNewswire/ -- ERS electronic , the industry leader of thermal management solutions for semiconductor manufacturing has finalized an agreement with Geringer Halbleitertechnik GmbH & Co. KG , a move poised to bolster its research and development (R&D) and production capabilities.

Key Points:

MUNICH, April 9, 2024 /PRNewswire/ -- ERS electronic , the industry leader of thermal management solutions for semiconductor manufacturing has finalized an agreement with Geringer Halbleitertechnik GmbH & Co. KG , a move poised to bolster its research and development (R&D) and production capabilities.
Geringer was founded in 1991 and has established itself as a reputable developer and manufacturer of tailor-made manufacturing machines for the semiconductor industry.
"We are thrilled to welcome the team from Geringer to ERS and expand our APEqS Business Unit," says Laurent Giai-Miniet, CEO of ERS electronic.
As I transition into retirement, I wish ERS all the best and am excited to see the great things they will accomplish."

Talkiatry Collaborates with HCA Healthcare Physician Practices and Urgent Care Centers To Help Improve Access to Quality Psychiatric Care

Retrieved on:

Wednesday, April 3, 2024

Diagnosis, Health, Partnership, EMR, Patient, Hospital, Cigna, Insurance, ERS, HCA Healthcare, DSM-IV codes, Nursing

Primary and urgent care providers that are part of HCA Healthcare's network can now easily refer patients to one of Talkiatry's 300+ full-time, board-certified psychiatrists when HCA Healthcare or community resources do not have capacity.

Key Points:

Primary and urgent care providers that are part of HCA Healthcare's network can now easily refer patients to one of Talkiatry's 300+ full-time, board-certified psychiatrists when HCA Healthcare or community resources do not have capacity.
Talkiatry augments the extensive behavioral health footprint that HCA Healthcare currently operates and can see patients virtually within days of booking an appointment.
Nashville-based HCA Healthcare is one of the nation's leading providers of healthcare services comprising 186 hospitals and approximately 2,400 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics, in 20 states and the United Kingdom.
"Given our expanding national footprint and shared attention to quality of care, Talkiatry is uniquely suited to support the providers at HCA Healthcare's physician practices and urgent care centers who may be looking for quick access to behavioral health care resources for their patients," said Talkiatry CEO and Co-Founder Robert Krayn .

Going Beyond ATS/ERS 2019 Guidelines for Your Respiratory Clinical Trials, Upcoming Webinar Hosted by Xtalks

Retrieved on:

Wednesday, March 27, 2024

American Thoracic Society, Doctor of Philosophy, EDT, ATS, ERS, Drug development

TORONTO, March 27, 2024 /PRNewswire-PRWeb/ -- Join this insightful webinar in which the expert speakers will explore the evolution of data quality assessments in respiratory drug development. Historically, adherence to enforced spirometry standards from the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines has been the acceptable measure of high-quality data. However, despite refinements made in 2019 to address limitations in the historical standards, inconsistencies and aberrant treatment effects remain a persistent challenge, raising concerns over data accuracy.

Key Points:

The featured speakers will discuss the limitations of traditional adherence to the American Thoracic Society (ATS)/European Respiratory Society (ERS)-enforced spirometry standards.
They will expore how improved data quality can accelerate drug development, reduce costs and enable better development decisions for personalized medicine.
TORONTO, March 27, 2024 /PRNewswire-PRWeb/ -- Join this insightful webinar in which the expert speakers will explore the evolution of data quality assessments in respiratory drug development.
Clario, a leader in clinical research and technology, has been initiating a more focused approach to ensure respiratory data accuracy within clinical trials.

Retail Clinic Utilization Increased 202 Percent Nationally from 2021 to 2022, according to Seventh Annual FAIR Health Report

Retrieved on:

Tuesday, March 26, 2024

Abdominal ultrasonography, COVID-19, FH, Patient, Policy, Radiology, ASC, FAIR, Hospital, Pathology, ERS, Medicine, E&M

NEW YORK, March 26, 2024 /PRNewswire/ -- Retail clinic utilization increased 202 percent nationally from 2021 to 2022, and emergency room (ER) utilization increased 138 percent.1 Retail clinics and ERs had the greatest increases in utilization among the places of service studied—which also included urgent care centers, telehealth and ambulatory surgery centers (ASCs)—in a new FAIR Health white paper containing the seventh annual edition of FH® Healthcare Indicators and FH® Medical Price Index. Like the previous editions, this year's edition of FH Healthcare Indicators and FH Medical Price Index is intended to provide perspective for all healthcare stakeholders in a rapidly changing healthcare environment.

Key Points:

Focusing on alternative places of service and ERs, FH Healthcare Indicators evaluate changes in utilization, geographic and demographic factors, diagnoses, procedures and costs.
Among the other key findings:
ASC utilization increased 88 percent nationally from 2021 to 2022; urgent care center utilization increased 43 percent and telehealth 8 percent in the same period.
Telehealth accounted for 3.9 percent of medical claim lines, urgent care centers 2.1 percent, ASCs 1.1 percent and retail clinics 0.2 percent.
The pathology and laboratory charge amount index increased four percent, while the surgery charge amount index increased three percent.

U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)

Retrieved on:

Friday, March 22, 2024

RARITAN, N.J., March 22, 2024 /PRNewswire/ -- Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved OPSYNVI® – a single-tablet combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor – for the chronic treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group I) and WHO functional class (FC) II-III.1 OPSYNVI® may be used in patients with PAH who are treatment-naïve or who are already on an ERA, PDE5 inhibitor or both. OPSYNVI® may be used in patients who are currently treated concomitantly with stable doses of macitentan 10 mg and tadalafil 40 mg (20 mg x 2) as separate tablets.1

Key Points:

Historically, this required patients to take multiple pills because no single-tablet combination therapy targeting two or more pathways was available," said Kelly Chin, M.D., Professor of Internal Medicine and Director of the Pulmonary Hypertension Program at UT Southwestern Medical Center, and an investigator in the A DUE study.
The FDA's approval of OPSYNVI® is based on the results from the pivotal Phase 3 A DUE study , in which OPSYNVI® demonstrated greater reduction in Pulmonary Vascular Resistance (PVR) after 16 weeks versus tadalafil or macitentan monotherapy.
"People with PAH often live with the burden of taking many pills each day, which can pose challenges," said James F. List, M.D., Ph.D., Global Therapeutic Area Head, whose team oversees a portfolio of programs including Pulmonary Hypertension at Johnson & Johnson.
"We're thrilled to bring this single-tablet combination therapy to patients, as it has the potential to optimize disease management and fulfill a significant unmet need in supporting recently updated treatment guidelines that call for initial or early combination treatment."

ERS electronic introduces the first semi-automatic machine of its Luminex product line featuring groundbreaking PhotoThermal debonding technology

Retrieved on:

Wednesday, March 13, 2024

Glass, Therapy, Luminex, New product development, Research, ERS, CLAL

MUNICH, March 13, 2024 /PRNewswire/ -- ERS electronic , the industry leader of thermal management solutions for semiconductor manufacturing is presenting the first machine from its innovative Luminex product line featuring the cutting-edge "PhotoThermal" debonding technology for wafer and panels up to 600 x 600 mm.

Key Points:

MUNICH, March 13, 2024 /PRNewswire/ -- ERS electronic , the industry leader of thermal management solutions for semiconductor manufacturing is presenting the first machine from its innovative Luminex product line featuring the cutting-edge "PhotoThermal" debonding technology for wafer and panels up to 600 x 600 mm.
PhotoThermal debonding is a zero stress debonding method that uses a highly controlled flash lamp to separate the carrier from the substrate.
ERS 's semi-automatic machine is the first in a series of machines belonging to the Luminex product line.
As part of the comprehensive product line, the company will offer the automatic machine with several modular add-ons, further enhancing product quality and yield.

ERS electronic introduces the first semi-automatic machine of its Luminex product line featuring groundbreaking PhotoThermal debonding technology

Retrieved on:

Wednesday, March 13, 2024

Glass, Therapy, Luminex, New product development, Research, ERS, CLAL

MUNICH, March 13, 2024 /PRNewswire/ -- ERS electronic , the industry leader of thermal management solutions for semiconductor manufacturing is presenting the first machine from its innovative Luminex product line featuring the cutting-edge "PhotoThermal" debonding technology for wafer and panels up to 600 x 600 mm.

Key Points:

MUNICH, March 13, 2024 /PRNewswire/ -- ERS electronic , the industry leader of thermal management solutions for semiconductor manufacturing is presenting the first machine from its innovative Luminex product line featuring the cutting-edge "PhotoThermal" debonding technology for wafer and panels up to 600 x 600 mm.
PhotoThermal debonding is a zero stress debonding method that uses a highly controlled flash lamp to separate the carrier from the substrate.
ERS 's semi-automatic machine is the first in a series of machines belonging to the Luminex product line.
As part of the comprehensive product line, the company will offer the automatic machine with several modular add-ons, further enhancing product quality and yield.

Community Health Systems Partners With Mark Cuban Cost Plus Drug Company to Address the Rising Cost of Drugs and Potential Drug Shortages

Retrieved on:

Thursday, March 7, 2024

Community Health Systems, Inc. (NYSE: CYH) (CHS) will become the first national healthcare system to purchase select pharmaceutical supplies from Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) as part of a new, collaborative relationship that promises to bring high-quality, lower cost drugs into the hospital setting.

Key Points:

Community Health Systems, Inc. (NYSE: CYH) (CHS) will become the first national healthcare system to purchase select pharmaceutical supplies from Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) as part of a new, collaborative relationship that promises to bring high-quality, lower cost drugs into the hospital setting.
Drug shortages – Cost Plus Drugs is focused on manufacturing drugs that are often in limited supply, threatening patient treatment and outcomes when shortages occur.
CHS and Cost Plus Drugs are working together to identify, prepare for, and mitigate potential future drug shortages in the hospital setting.
“Community Health Systems has stepped forward to consider important issues related to drug supply, drug costs, patient care and outcomes,” said Alex Oshmyansky, MD, PhD, Chief Executive Officer of Mark Cuban Cost Plus Drug Company.

DP World Prince Rupert Boosts Efficiency, Reliability in the Global Supply Chain

Retrieved on:

Tuesday, February 27, 2024

Rail, Maritime, Transport, Logistics, Supply Chain Management, ERS, Gateway, Album-equivalent unit, Port of Prince Rupert, DP World, Ocean Alliance, DP, Canadian National Railway, Partnership

This includes routing customers through Canada’s Port of Prince Rupert, which boasts several strategic advantages for North American customers seeking efficiency and reliability in their supply chain operations.

Key Points:

This includes routing customers through Canada’s Port of Prince Rupert, which boasts several strategic advantages for North American customers seeking efficiency and reliability in their supply chain operations.
Speed and Agility: To minimize delays throughout the entire value chain, DP World Prince Rupert emphasizes reduced dwell times and swift cargo movement.
Global Connectivity: Marine access from DP World Prince Rupert to Asia through three major alliances – Ocean Alliance, 2M Alliance, and T.H.E.
Shaun Stevenson, President & CEO, Prince Rupert Port Authority, underscored the port's strategic advantages: “The Port of Prince Rupert provides fast and reliable supply chain solutions for trans-Pacific trade.